Research programme: erythropoietin mimetics - STATegics

Drug Profile

Research programme: erythropoietin mimetics - STATegics

Alternative Names: STS-E15

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator STATegics
  • Class Erythropoietins; Small molecules
  • Mechanism of Action Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Brain injuries; Friedreich's ataxia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Friedreich's ataxia in USA
  • 16 Jul 2016 No recent reports of development identified for research development in Brain injuries in USA
  • 16 Nov 2010 STATegics receives the Applied Research and Technology Development Award (ARATDA) award from the US Department of Defense for erythropoietin mimetics development in traumatic brain injury
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top